Elisa Scarselli

Elisa Scarselli

Company: Nouscom

Job title: CSO and Co-founder

Seminars:

Panel Discussion: Evaluating Combination Therapies 3:00 pm

The hasty evolvement of combination strategies Combinational therapies employing both neoantigen-based approaches and immune checkpoint blockade (ICB) are underway to overcome ICB-induced immune resistance and maximize antitumor immune activity Investigating the safety and efficacy of neoantigen vaccine therapy plus chemotherapy in adjuvant setting Discuss regulatory pathway and limitations to approve two new drugs How to…Read more

day: Day Two

Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression 2:30 pm

Nouscom Cancer vaccines targeting neoantigens: Rely on effective neoantigens prediction methods Can encode a large number of neoantigens Induce a robust neoantigens’ specific CD4 and CD8 T cell immunity Cure large established tumours in mice when combined with checkpoint blockadeRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.